相似文献
1
The first 30 years of p53: growing ever more complex.
Nat Rev Cancer. 2009 Oct;9(10):749-58. doi: 10.1038/nrc2723.
2
Recent advances in p53 research and cancer treatment.
J Biomed Biotechnol. 2011;2011:978312. doi: 10.1155/2011/978312. Epub 2011 Jun 16.
3
The expanding universe of p53 targets.
Nat Rev Cancer. 2009 Oct;9(10):724-37. doi: 10.1038/nrc2730.
4
A History of Cancer Research: The P53 Pathway.
Cold Spring Harb Perspect Med. 2025 Feb 3;15(2):a035931. doi: 10.1101/cshperspect.a035931.
5
Death squads enlisted by the tumour suppressor p53.
Biochem Biophys Res Commun. 2005 Jun 10;331(3):786-98. doi: 10.1016/j.bbrc.2005.03.183.
6
To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
Hum Exp Toxicol. 1995 Feb;14(2):222-5. doi: 10.1177/096032719501400213.
7
The role of p53-target genes in human cancer.
Crit Rev Oncol Hematol. 2000 Jan;33(1):1-6. doi: 10.1016/s1040-8428(99)00051-7.
8
p53 and human cancers.
Br Med Bull. 1994 Jul;50(3):582-99. doi: 10.1093/oxfordjournals.bmb.a072911.
9
p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis.
J Nippon Med Sch. 2006 Apr;73(2):54-64. doi: 10.1272/jnms.73.54.
10
Understanding p53 tumour suppressor network.
Biol Direct. 2021 Aug 6;16(1):14. doi: 10.1186/s13062-021-00298-3.
引用本文的文献
1
Stratifying Skin Cancer Patients and Guiding Treatment Decisions Through Combined p53 and p63 Expression Analysis.
In Vivo. 2025 Sep-Oct;39(5):2599-2608. doi: 10.21873/invivo.14060.
2
Integrative Transcriptomic and Network Pharmacology Analysis Reveals Key Targets and Mechanisms of (musk) Against Viral Respiratory Tract Infections.
Pharmaceuticals (Basel). 2025 Jul 30;18(8):1136. doi: 10.3390/ph18081136.
3
Elucidating the Role of in Regulating Cancer Cell Growth via the Modulation of p53 and c-Myc Expression.
Curr Issues Mol Biol. 2025 Aug 4;47(8):615. doi: 10.3390/cimb47080615.
4
Artemisiae Annuae Herba: from anti-malarial legacy to emerging anti-cancer potential.
Theranostics. 2025 Jun 20;15(15):7346-7377. doi: 10.7150/thno.115414. eCollection 2025.
5
Activation of Pvt1b isoform contributes to local Pvt1 abundance to repress Myc during stress.
PLoS Genet. 2025 Jul 31;21(7):e1011790. doi: 10.1371/journal.pgen.1011790. eCollection 2025 Jul.
6
LINE1 insertion into the NACC2 locus disrupts the HDM2 axis and activates lung oncogenic signaling.
NPJ Precis Oncol. 2025 Jul 24;9(1):255. doi: 10.1038/s41698-025-01050-0.
7
Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation.
Elife. 2025 Jul 21;14:RP106469. doi: 10.7554/eLife.106469.
8
PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7.
Hemasphere. 2025 Jul 13;9(7):e70149. doi: 10.1002/hem3.70149. eCollection 2025 Jul.
9
RFC1 regulates the expansion of neural progenitors in the developing zebrafish cerebellum.
Nat Commun. 2025 Jul 1;16(1):6019. doi: 10.1038/s41467-025-60775-5.
10
Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.
Biomolecules. 2025 May 26;15(6):763. doi: 10.3390/biom15060763.
本文引用的文献
1
The expanding universe of p53 targets.
Nat Rev Cancer. 2009 Oct;9(10):724-37. doi: 10.1038/nrc2730.
2
When mutants gain new powers: news from the mutant p53 field.
Nat Rev Cancer. 2009 Oct;9(10):701-13. doi: 10.1038/nrc2693. Epub 2009 Aug 20.
3
A common genetic mechanism in malignant bone marrow diseases.
N Engl J Med. 2009 May 28;360(22):2355-7. doi: 10.1056/NEJMe0902257.
4
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans.
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9761-6. doi: 10.1073/pnas.0904280106. Epub 2009 May 22.
5
The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Mol Cancer Res. 2009 May;7(5):713-23. doi: 10.1158/1541-7786.MCR-08-0247. Epub 2009 May 12.
6
Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.
Cancer Cell. 2009 May 5;15(5):441-53. doi: 10.1016/j.ccr.2009.03.021.
7
Blinded by the Light: The Growing Complexity of p53.
Cell. 2009 May 1;137(3):413-31. doi: 10.1016/j.cell.2009.04.037.
8
Cytoplasmic functions of the tumour suppressor p53.
Nature. 2009 Apr 30;458(7242):1127-30. doi: 10.1038/nature07986.
9
A review of contusugene ladenovec (Advexin) p53 therapy.
Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
10
p53 polymorphisms: cancer implications.
Nat Rev Cancer. 2009 Feb;9(2):95-107. doi: 10.1038/nrc2584.
Zotero 插件